跳至主要内容
临床试验/NL-OMON55494
NL-OMON55494已完成不适用

SuperPath® a pilot study - Superpath pilotstudy

Reinier Haga Orthopedisch Centrum0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patient is 18 to 75 years of age, inclusive
  • Patient is able to speak and write Dutch
  • Patient qualifies for primary unilateral total hip arthroplasty
  • (THA) based on physical exam and medical history including at least one of
  • the following:
  • o Osteoarthritis
  • o Avascular necrosis (AVN)
  • o Inflammatory arthritis
  • o Rheumatoid arthritis with adequate bone quality
  • o Post-traumatic arthritis
  • o Congenital hip dysplasia., •Patient has no history of previous total hip
  • replacement or arthrodesis of the affected hip
  • Patient is willing and able to provide written informed consent.

排除标准

  • Subjects will be excluded when they meet one or more of the following
  • contra-indications for the SuperPath® technique:
  • Infection, sepsis, and osteomyelitis
  • Patients with a low femoral offset
  • Uncooperative patient or patient with neurologic disorders who are incapable
  • of following directions
  • Insufficient bone stock to provide adequate support and/or fixation to the
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption apparent on
  • roentgenogram
  • Vascular insufficiency, muscular atrophy, neuromuscular disease ,
  • Additionally, subjects will be excluded when they meet the following exlusion
  • Patients with emergency or semi-emergency THA (e.g. for treatment of femoral
  • neck fractures)
  • Patient has a known or suspected sensitivity or allergy to one or more of the
  • implant materials
  • Revision THA surgery of the ipsilateral side
  • Contralateral THA <6 months before current surgery

研究者

发起方
Reinier Haga Orthopedisch Centrum

相似试验

SuperPath® a pilot study | 临床试验